Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for $^{177}$Lu-Labeled PSMA-Targeting Peptides

Peter Kletting$^1$*, Christiane Schuchardt$^2$, Harshad R. Kulkarni$^2$, Mostafa Shahinfar$^2$, Aviral Singh$^2$, Gerhard Glatting$^3$, Richard P. Baum$^2$, Ambros J. Beer$^1$

1 Department of Nuclear Medicine, Ulm University, Ulm, Germany, 2 THERANO STICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Zentralklinik Bad Berka, Bad Berka, Germany, 3 Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

*peter.kletting@uniklinik-ulm.de

Abstract

In molecular radiotherapy with $^{177}$Lu-labeled prostate specific membrane antigen (PSMA) peptides, kidney and/or salivary glands doses limit the activity which can be administered. The aim of this work was to investigate the effect of the ligand amount and injected activity on the tumor-to-normal tissue biologically effective dose (BED) ratio for $^{177}$Lu-labeled PSMA peptides. For this retrospective study, a recently developed physiologically based pharmacokinetic model was adapted for PSMA targeting peptides. General physiological parameters were taken from the literature. Individual parameters were fitted to planar gamma camera measurements ($^{177}$Lu-PSMA I&T) of five patients with metastasizing prostate cancer. Based on the estimated parameters, the pharmacokinetics of tumor, salivary glands, kidneys, total body and red marrow was simulated and time-integrated activity coefficients were calculated for different peptide amounts. Based on these simulations, the absorbed doses and BEDs for normal tissue and tumor were calculated for all activities leading to a maximal tolerable kidney BED of $10\,\text{Gy}_{2.5}/\text{cycle}$, a maximal salivary gland absorbed dose of $7.5\,\text{Gy}/\text{cycle}$ and a maximal red marrow BED of $0.25\,\text{Gy}_{15}/\text{cycle}$. The fits yielded coefficients of determination $>0.85$, acceptable relative standard errors and low parameter correlations. All estimated parameters were in a physiologically reasonable range. The amounts (for $2^{5} - 2^{9} \,\text{nmol}$) and pertaining activities leading to a maximal tumor dose, considering the defined maximal tolerable doses to organs of risk, were calculated to be $272\pm253 \,\text{nmol}$ (452$\pm$420 $\mu\text{g}$) and $7.3\pm5.1 \,\text{GBq}$. Using the actually injected amount ($235\pm155 \,\mu\text{g}$) and the same maximal tolerable doses, the potential improvement for the tumor BED was 1–3 fold. The results suggest that currently given amounts for therapy are in the appropriate order of magnitude for many lesions. However, for lesions with high binding site density or lower perfusion, optimizing the peptide amount and activity might improve the tumor-to-kidney and tumor-to-salivary glands BED ratio considerably.
**Introduction**

Molecular radiotherapy using $^{177}$Lu-labeled PSMA specific peptides is a promising novel approach for the treatment of metastatic prostate cancer [1–3]. However, PSMA is also expressed with relevant density in the salivary glands [4] and kidneys [5], where specific binding in combination with (possible) unspecific uptake can lead to considerable absorbed doses [6, 7]. To increase the tumor-to-kidney absorbed dose or biologically effective dose (BED) ratio, amino acids are administered to block unspecific uptake at some institutions analogous to peptide receptor radionuclide therapy (PRRT), however evidence on the relevance of this approach for PSMA-targeted radionuclide therapy is still missing. In addition, research is directed to block PSMA specific uptake using 2-(phosphonomethyl)pentanedioic acid (PMPA) [8]. However, the effect of the peptide amount and the administered activity on the tumor, kidneys, salivary glands and red marrow absorbed dose and BED has not been investigated. For a systematic investigation, physiologically based pharmacokinetic (PBPK) modeling, that allows simulating the pharmacokinetics for different peptide amounts using general physiological and patient individual parameters estimated based on imaging data, represents a suitable method [9, 10]. To ensure the clinical relevance of these simulations, the pharmacokinetic model should be combined with absorbed dose and BED calculations and boundary conditions such as the maximal tolerable dose for critical organs. Recently, we have developed and demonstrated such a method for optimizing the peptide amount and activity for molecular radiotherapy with $^{90}$Y-DOTATATE [11] to improve the tumor-to-kidney BED ratio. A high tumor-to-kidney ratio for binding site density together with a low ratio for tumor-to-kidney perfusion resulted in a strong influence of the peptide amount on the BED ratio. These results were in agreement with other studies for similar substances [12, 13]. We conjectured an even stronger effect for PSMA targeting ligands, as high tumor binding site densities compared to normal tissue have been reported in vitro [14–16].

Therefore, the aim of this work was to investigate the effect of ligand amount and injected activity on the tumor-to-kidney and tumor-to-salivary gland BED ratio for therapy with $^{177}$Lu-labeled PSMA peptides. Maximal tolerable doses of the kidneys, salivary glands and red marrow were assumed. For that purpose a whole body PBPK model and a simulation algorithm were implemented and adapted to PSMA ligands [11]. Patient individual parameters were fitted to time-activity data of five patients with metastasizing prostate cancer treated with $5.6\pm0.3$ GBq $^{177}$Lu-PSMA I&T. Based on the individually estimated parameters, the tumor, kidney, salivary gland and red marrow pharmacokinetics were simulated for large ranges of peptide amounts and activities. Absorbed doses and BEDs were calculated considering a maximal red marrow BED of 0.25 Gy$_{15}$/cycle, a maximal kidney BED of 10 Gy$_{2.5}$/cycle and/or a maximal salivary gland absorbed dose of 7.5 Gy/cycle. The maximal tolerable doses were derived from literature values assuming four cycles with equal biodistribution. The effect of the tumor perfusion on the predicted BED for different amounts was also investigated.

**Materials and Methods**

**Patients/Data**

Data of five patients (one cycle per patient) with metastasizing prostate cancer were included (Table 1). For patient 1 data of the second cycle, for patients 2–5 data of the first cycle were used. Before PSMA radioligand therapy, each patient was informed about the therapeutic procedure and possible adverse effects. $^{177}$Lu-PSMA was administered in compliance with the German Medicinal Products Act, AMG (§13, 2b), the 1964 Helsinki declaration, and in accordance with the responsible regulatory body (Government of Thuringia, Germany). The study
was performed in accordance with German regulations (Federal Agency for Radiation Protection) concerning radiation safety and was approved by the local ethics committee (Bad Berka, Germany). Written informed consent was obtained from all patients.

The patient selection criteria for therapy are described in [17]. PSMA expression of tumors and metastatic lesions was verified before therapy using $^{68}$Ga-PSMA PET/CT ($^{68}$Ga-PSMA-H-BED-CC). The administered therapeutic activity, number of cycles and interval between cycles were selected based on the uptake in tumor lesions on pre-therapeutic $^{68}$Ga-PSMA PET/CT, kidney function (serum creatinine, tubular extraction rate, TER determined by $^{99m}$Tc-MAG3 scintigraphy and creatinine-clearance), hematological reserve, previous treatments and general status of the patient (KPS). The administered activity in this patient group was relatively homogeneous with $5.6\pm0.3$ GBq $^{177}$Lu-PSMA.

For all patients $\gamma$-camera imaging was performed at least 4 times after beginning of the therapy infusion (Fig 1). P1: 0.5 h, 2 h, 1 d, 2 d, 3 d; P2: 0.5 h, 2 h, 1 d, 2 d, 3 d; P3: 0.5 h, 2 h, 1 d, 4 d; P4: 0.5 h, 2 h, 1 d, 2 d, 5 d; P5: 0.5 h, 2 h, 1 d, 2 d, 3 d. The kidney function, i.e. the tubular extraction rate (TER), was determined using the $^{99m}$Tc-Mag$_3$ method [18].

**Labeling and amino acid infusion.** Lutetium-177 labeling of the PSMA I&T ligand was performed according to a previously published method [19]. For therapy $236\pm155$ μg PSMA labeled with $5.6\pm0.3$ GBq $^{177}$Lu were intravenously injected as a 10 min infusion. Lysine and arginine (1000 ml, 2.5% infusion) were co-administered over a period of 2 h, starting 0.5 h prior to the administration of $^{177}$Lu-PSMA.

**Data acquisition and processing.** Data acquisition and processing was based on MIRD pamphlets 16 [20] and 21 [21] as described in [17, 22]. In brief, planar whole-body scintographies (anterior and posterior) were acquired with a double-head $\gamma$-camera (MEDISO spirit DH-V, Medical Imaging Systems, Budapest, Hungary). Regions of interest (ROIs) were drawn manually over the source organs. First, ROIs were drawn by using the scan showing the best tumor to background ratio (mostly the scan acquired 20 or 44 h following an injection). Then, the ROIs were applied to the other 4 scans and the respective counts were obtained. The scintographies were analyzed using the HERMES system (Hermes Medical Solutions, Stockholm, Sweden). To quantify the ROI data, the geometric mean of anterior and posterior counts with background corrections was used for each organ and target lesion ROI. Based on the corrected counts, the time-dependent activities for the considered regions were calculated [22]. ROIs were always drawn by the same physicist (C.S.), in collaboration with a nuclear medicine

| Patient | Age | BSA [m$^2$] | Amount$^a$ [nmol] | Activity[GBq] | TER[ml/min] | Measured volumes [ml] |
|---|---|---|---|---|---|---|
| Parotidglands$^b$ | Kidneys$^b$ | Tumor 1 | Tumor 2 |
| P1 | 76 | 2.0 | 148 | 6.0 | 198 | 54 | 321 | 0.5 | 1 |
| P2 | 69 | 1.9 | 98 | 5.4 | 201 | 21 | 311 | 1 | 34 |
| P3 | 78 | 1.8 | 89 | 5.4 | 136 | 17 | 394 | 2 | 13 |
| P4 | 54 | 2.1 | 74 | 5.4 | 252 | 52 | 268 | 4 | 3 |
| P5 | 53 | 2.0 | 302 | 5.6 | 176 | 29 | 296 | 1.5 | 1 |
| Mean | 66 | 2.0 | 142 | 5.6 | 193 | 35 | 318 | 6 |
| SD | 12 | 0.1 | 94 | 0.3 | 42 | 17 | 47 | 10 |

Abbreviation: BSA = Body surface area, TER = tubular extraction rate as determined with the $^{99m}$Tc Mag$_3$ method.

$^a$1.66 μg of the ligand corresponds to 1 nmol.

$^b$The volumes of the parotid glands as well as the kidney volumes were added to one volume.

Abbreviation: BSA = Body surface area, TER = tubular extraction rate as determined with the $^{99m}$Tc Mag$_3$ method.
physician, who decided which lesions were relevant for dosimetry. In this study, ROIs were
drawn for two tumor lesions (bone and lymph nodes), parotid glands, kidneys, and total body.
The volume of the tumor lesions, left and right parotid glands and the kidneys were deter-
mined using CT [23]. Lesions showing high uptake and no superimposition with organs or
other lesions were selected.

In the following calculations, the term salivary glands is synonymous to the total volume
and activity of the right and left parotid glands. The parotid glands are assumed representative
for all salivary glands. The relatively large volume makes them most suitable for activity deter-
mination from planar images.

**PBPK model**

**PBPK Model structure.** The global structure of a recently developed whole-body PBPK
model [11] was applied. The model includes all major physiological and physical mechanisms,
i.e. blood flow, extravasation, specific binding, internalization, degradation and release, physical decay and clearance [11]. Labeled and unlabeled peptides are described separately (assuming equal physiological parameters) and coupled by the competition for binding to free binding sites and by physical decay. This model (structure and parameters) was adapted to PSMA ligands, i.e. the adrenals were replaced by the salivary glands and all parameter values describing target-ligand interaction were substituted with the PSMA I&T relevant values, as described in S1 File and below. Tumor, salivary glands, kidney, liver, spleen, gastrointestinal tract and prostate were assumed to be accessible PSMA positive tissues [5, 24]. Muscle, fat tissue, lungs, bone, red marrow, heart, brain and skin were explicitly modeled non-PSMA expressing normal tissues. All organs are connected via blood flow. Extravasation to the interstitial spaces is diffusion dominated for the small peptides. Therefore, transcapillary transport is described by the permeability surface area product and the vascular and interstitial volumes of the pertaining tissue. The complex internalization (recycling), metabolism and release process was described with one internalization and one release rate, representing effective values. It is also assumed that unspecific kidney uptake is predominately blocked by the administration of amino acids [11] although this is not proven for PSMA I&T.

**PBPK model parameters and model fitting.** SAAMII [25] (version 2.2, The Epsilon Group, Washington, USA) was employed for modeling and fitting using the settings as described earlier [9]. All parameters and the pertaining values are taken from literature and given in Table A in S1 File. Cell release rates $\lambda_{\text{release}}$ for tumor, kidney and salivary glands were fitted. The binding site density of tumor lesions [R$_{\text{TU,0}}$], kidneys [R$_{\text{K,0}}$] and salivary glands [R$_{\text{SAL,0}}$] were fitted, for all other tissue relative values according to [5, 24] were assumed. Internalization rates were fixed to $\lambda_{\text{int}} = 0.001 \text{ min}^{-1}$ for all organs and tumor [11]. Weinseien et al. report rapid internalization [26], however, preliminary fits with $\lambda_{\text{int}} = 0.01 \text{ min}^{-1}$ did not lead to adequate results, i.e. low coefficients of determination, high parameter standard deviations and low Akaike weights compared to fits using $\lambda_{\text{int}} = 0.001 \text{ min}^{-1}$. For the tumor, a perfusion rate $f_{\text{TU}}$ of 0.5 ml g$^{-1}$ min$^{-1}$ was assumed [27]. The adjustable parameters (Table 2, S1 and S2 Files) were fitted to the time activity data of each patient. The number of free parameters was 10 for each patient and the sample size 20 for patient 2 and 25 for all other patients. Note that relative fitting was used to estimate the variance for the data set of each organ. Thus the ratio of sample size to free parameters (+1 for the variance) was 1.3–1.7, which is acceptable.

Although background correction using a ROI on the thigh and equation 6 from MIRD 16 [20] was applied, inaccuracies of the correction method substantially affect early

| Parameter | [R$_{\text{K,0}}$] | [R$_{\text{SAL,0}}$] | [R$_{\text{TU,0}}$] | $\lambda_{\text{K,release}}$ | $\lambda_{\text{SAL,release}}$ | $\lambda_{\text{TU,release}}$ | $f_{\text{SAL}}$ |
|-----------|-----------------|-----------------|-----------------|------------------|------------------|------------------|-----------------|
| Mean      | 27              | 62              | 380             | 2.88             | 3.90             | 1.76             | 0.20            |
| SD        | 12              | 31              | 620             | 0.55             | 0.63             | 0.58             | 0.19            |
| Median    | 24              | 42              | 110             | 2.9              | 3.7              | 2.0              | 0.16            |
| Min       | 14              | 38              | 19              | 2.3              | 3.3              | 0.88             | 0.074           |
| Max       | 46              | 108             | 2412            | 3.7              | 4.8              | 2.4              | 0.53            |
| Literature|                 |                 | 266–1328$^a$    | 0.5–2.3$^b$      | -                | 0–3$^c$          | 0.34±0.09$^c$   |

Abbreviation: [R$_{\text{i,0}}$] binding site density of kidneys, salivary glands and tumor, $\lambda_{\text{release}}$ release rate of kidneys, salivary glands and tumor, $f_{\text{SAL}}$ serum flow per mass of salivary glands

$^a$ Assuming 10$^{12}$ cells/l and 180.000 [16] and 800.000 [14] copies of PSMA/cell from in vitro measurements

$^b$ For $^{111}$In-DOTATATE [11]

$^c$ [42] non-stimulated blood flow per mass

doi:10.1371/journal.pone.0162303.t002
measurements. This is due to different tissue thicknesses, different background activities or a considerable larger tumor ROI diameter (especially for small lesions) compared to the actual tumor diameter. The tumor volume was determined using CT. Therefore, as we were interested in the underlying physiology (not only in the time-integrated activity coefficient) like the binding site density, an additional correction was necessary. This was done by assigning a fraction (adjustable parameter) to the muscle compartments (S1 File, page 19). PBPK models allow such corrections by assigning the measurements to the compartments which contribute to the total measurement value.

**PBPK Model validation and selection.** Reported values for the PSMA ligand dissociations constants from in vitro cell studies (~ 8 nM, [26]) and BiaCore measurements (~ 1 nM, [28]) differ considerably. Therefore, two different dissociation rates $k_{\text{off}}$, i.e. 0.046 $\text{min}^{-1}$ (Model 1) and 0.46 $\text{min}^{-1}$ (Model 2), were assumed. The association rate was fixed to $k_{\text{on}} = 0.046 \text{ l nmol}^{-1} \text{min}^{-1}$ [28]. The models were compared using the Akaike information criterion (AIC) [29, 30]. The AIC represents an elegant method to select the model most supported by the data. It is suitable for the data at hand [29, 30] and requires solely the sums of squares and the numbers of measurements and adjustable parameters (+1 if the variance is also estimated). The fits were validated by visual inspection, coefficients of determination and correlation, physiological plausibility and standard deviations of the estimated parameters [31].

**Simulations**

The simulations were conducted to investigate the effect of the peptide amount on the tumor-to-normal tissue absorbed dose or BED ratio. For the simulations, the PBPK model which was developed and used for fitting was implemented in MATLAB/Simulink version 2014b (The MathWorks, Inc., Natick, Massachusetts, United States). All calculation steps were conducted employing one Simulink model, i.e. the PBPK model was combined with additional mathematical operations required for BED calculations.

**From pharmacokinetics to BED.** The BED was calculated to take into account the dose rate and radiobiological parameters [32]. The pharmacokinetics of labeled and unlabeled peptide, the fraction of administered activity $a_i(t)$, the corresponding time-activity curve $A_i(t)$ in each organ $i$ and the absorbed dose rate $\dot{D}_i(t)$ were simulated.

For salivary glands, tumor and kidney only the self-doses were considered according to

$$\dot{D}_i(t) = A_i(t) \cdot S_{i-i} = A_{\text{inj}} \cdot a_i(t) \cdot S_{i-i}$$  \hspace{1cm} (1)

where $A_{\text{inj}}$ is the injected activity and $S_{i-i}$ represents the self-absorbed dose rate per unit activity of organ $i$.

For red marrow the self-dose and the irradiation from the remainder were considered [33] according to

$$\dot{D}_{\text{RM}} = A_{\text{RM}}(t) \cdot S_{\text{RM-REM}} + A_{\text{REM}}(t) \cdot S_{\text{RM-REM}}$$  \hspace{1cm} (2)

where $S_{\text{RM-RM}}$ represents the self-absorbed dose rate per unit activity of red marrow and $S_{\text{RM-REM}}$ the absorbed dose rate per unit activity of remainder to red marrow. $A_{\text{RM}}(t)$ and $A_{\text{REM}}(t)$ are the time-activity curves of the red marrow and the remainder.

The absorbed dose was determined by numerical integration according to

$$D_i(T) = \int_0^T \dot{D}_i(t) \, dt$$  \hspace{1cm} (3)

with $T = 3 \cdot 10^4 \text{ min}$. The BED of all relevant organs was calculated using the absorbed dose and
the Lea–Catcheside factor $G_i$ (Eq. 17, S1 File) [32] of each individual dose rate according to

$$\text{BED}_i = D_i \cdot \left(1 + \frac{G_i}{\alpha/\beta_i} \cdot D_i\right) \tag{4}$$

**Maximal tolerable doses.** For PRRT with $^{90}$Y a BED-effect relationship for the kidney could be established [34]. Although several dosimetry studies with two $^{177}$Lu-PSMA compounds have been conducted, for this therapy maximal tolerable doses are still unknown and the optimal number of cycles has not been identified [35]. Here, we assumed 4 therapy cycles having equal biodistributions. We further assumed a maximal cumulative kidney BED of 40 Gy$_{2.5}$ [36] based on data from PRRT with $^{90}$Y. A maximal cumulative salivary absorbed dose of 30 Gy from experiences in radiation therapy, which was used in a recent initial study for PSMA-617 [6], was also employed here. Usually, for the red marrow 2 Gy are assumed, however, due to possible irradiation from bone metastases (which were here included in the remainder), the value was reduced to 1 Gy$_{15}$. Therefore, the maximal kidney BED for one cycle was set to 10 Gy$_{2.5}$. The absorbed dose for salivary gland was set to 7.5 Gy and for red marrow BED to 0.25 Gy$_{15}$. For salivary glands no reliable value for a maximal tolerable BED could be found in the literature, therefore, instead of BED the absorbed dose was used as boundary condition. Nevertheless, the BEDs of the salivary glands were calculated as all needed information is available.

**Absorbed dose rates per unit activity (S-values).** S-values [37] and radiobiological parameters $\alpha/\beta$ and $\mu$ [32, 38–41] were taken from the literature (S1 File). The red marrow S-values were determined individually for each patient, i.e. the red marrow to red marrow S-value was scaled using body weight, the remainder to red marrow S-value was corrected according to Eqs 6, 13 and 22 in Hindorf et al. [33]. For tumor and salivary gland, spherical shapes were assumed [37]. For each individual volume of the salivary glands and tumor, the S-values were either taken directly from OLINDA [37] or derived by logarithmic interpolation. For metastases the same radiobiological parameters as for primary prostate cancer were used [40]. As there is an open discussion regarding the relevance of the salivary glands as a dose limiting organ, both scenarios were investigated, i.e. kidneys or salivary glands dose limiting and kidney and salivary glands dose limiting.

**Activities to administer, absorbed doses and BEDs.** In the first step all allowed combinations are identified, i.e. iso-dose curves for kidneys and salivary glands were generated. Simulations with smaller and larger than usually applied therapeutic amounts were used to demonstrate the effect for a wide range [11]. Activities to administer were calculated for amounts of 2−2$^{13}$ nmol (in steps of factor 2) and the constraints (for one cycle): kidney BED of 10 Gy$_{2.5}$ (case 1) or salivary glands absorbed dose of 7.5 Gy (case 2).

For kidneys and each amount $j$ (case 1):

$$-\tilde{a}_{K_j}(T) + \sqrt{\tilde{a}_{K_j}(T)^2 + \frac{8 \cdot \int_0^T a_{K_j}(t) dt \cdot \int_0^t a_{K_j}(\omega) \cdot e^{-\mu K_j(t-\omega)} d\omega \cdot \text{BED}_{K,\text{fixed}}}{\alpha_K/\beta_K}}$$

$$= \frac{4 \cdot S_{K-K} \cdot \int_0^T a_{K_j}(t) dt \cdot \int_0^t a_{K_j}(\omega) \cdot e^{-\mu K_j(t-\omega)} d\omega}{\alpha_K/\beta_K} \tag{5}$$

Eq 5 is derived in S1 File pages 9–10. $A_{\text{inj}1,j}$ is the activity to administer leading to a kidney BED of 10 Gy$_{2.5}$, $\tilde{a}_{K_j}(T)$ is the time-integrated activity coefficient, $a_{K_j}(t)$ the fraction of administered activity in the kidneys for each amount $j$ and $\text{BED}_{K,\text{fixed}}$ the maximal tolerable...
biologically effective dose (10 Gy$_{2.5}$) and $S_{K}$ the self-absorbed dose rate per unit activity of the kidneys.

For salivary glands (Eq. 21, S1 File) and each amount (case 2):

$$A_{SAL,j} = \frac{D_{SAL,\text{fixed}}}{\bar{a}_{SAL,j}(T) \cdot S_{SAL-SAL}}$$ (6)

where $\bar{a}_{SAL,j}(T)$ is the time-integrated activity coefficient for each amount $j$, $D_{SAL,\text{fixed}}$ the maximal tolerable absorbed dose and $S_{SAL-SAL}$ the self-absorbed dose rate per unit activity of the salivary glands.

The absorbed doses and BEDs for all organs were then calculated based on Eqs 1–4 above for the amounts $j$ and maximum activities to administer.

**Optimal tumor dose.** In a subsequent step, all amounts and pertaining activities, which led to red marrow BED $> 0.25$ Gy$_{15}$, were excluded as the red marrow is considered dose limiting. Thus, only for amounts and pertaining activities, which led to a red marrow BED $< 0.25$ Gy$_{15}$, the optimal tumor dose considering the kidney (case 1) or the salivary glands (case 2) as dose limiting organ was identified.

**Comparing optimal and actually used amounts.** To consider the kidneys and the salivary glands as dose limiting organ and to account for radiochemical limitations (maximal possible specific activity), a new set of combinations was assembled using the activities from case 1 and case 2 for each amount from $2^5-2^9$ nmol. All amounts and pertaining activities, which led to red marrow BED $> 0.25$ Gy$_{15}$, were excluded. From the remaining combinations, the optimal tumor dose was identified and compared to the “actual” tumor dose. The actual tumor dose was determined using the actual amount and an activity that would have led to a salivary gland absorbed dose of 7.5 Gy and kidney BED $< 10$ Gy$_{2.5}$ or kidney BED of 10 Gy$_{2.5}$ and absorbed dose $< 7.5$ Gy.

**Tumor perfusion sensitivity analysis.** A sensitivity analysis regarding the influence of the assumption for tumor perfusion was conducted. Perfusion is an important parameter for small molecules. It had to be fixed in the fitting process due to high correlation with the binding site density. Four different values for the perfusion rates 0.01, 0.1, 0.5 and 1 ml/g/min were investigated. The models were fitted to the data of each individual patient and compared using the Akaike weights based on the AIC [29, 30]. Subsequently, simulations as described above were conducted for models with Akaike weight $>1%$.

## Results

### Fitting and validation

Visual inspection showed good fits. The coefficient of determination $R^2$ was $> 0.85$ for all curves. A typical fit is depicted in Fig 2. All fits yielded coefficients of variation (relative standard errors) $< 50\%$ for any estimated parameter, except for the estimated tumor ROI background correction fraction $c_2$ (60%) for P5 (S2 File). Elements of the correlation matrix were $< 0.8$ except for the tumor release rate and binding site density of P1 (0.85), P2 (0.86) and P6 (0.84) and the salivary glands release rate and binding site density for P2 (0.82) [31]. Model 1 was more supported by the data: for all patients the Akaike weights were $> 0.9$. Thus, only the estimated parameters of model 1 were further used. The values of the estimated physiological parameters (Table 2) compare favorably to literature values, i.e., they are in a physiologically reasonable range [11, 14, 16, 42]. The results of each individual patient are presented in S2. The estimated fractional standard deviations for the tumor, salivary glands and the kidney data sets for P1-5 were 3–25%, 4–15% and 5–27%, respectively.
Simulations

Simulations for the median normal tissue parameters and mean/median tumor parameters (Table 2) are depicted in Fig 3. The graphs for each individual patient are presented in S2. The optimal amount and pertaining activities for kidney BED of 10 Gy\textsubscript{2.5} or salivary absorbed dose of 7.5 Gy (for red marrow BED < 0.25 Gy\textsubscript{15}) and the corresponding tumor absorbed doses and BEDs are provided in Table 3. Considering solely the kidneys (case 1) or salivary glands (case 2) as dose limiting organ, the median optimal amount and pertaining activity was 192 nmol (range: 2–512 nmol) and 9.3 GBq (range: 7.9–22.5 GBq) and 257 nmol (range: 2–2048 nmol) and 4.9 GBq (range: 2.4–16.5 GBq), respectively. The maximal possible tumor-to-kidneys BED ratio depends predominately on the ratio of binding site density (for a given organ volume). In addition, higher interstitial and serum volumes and unspecific uptake in the kidneys reduce the maximal possible tumor-to-kidneys BED ratio. The actual BED ratio (achieved in actual clinical scenario) predominately depends on the ratio of perfusion (see Fig 4), binding site density and the actually administered amount. With higher amounts also unspecific uptake (although assumed to be low) becomes more important. In addition, for higher amounts serum and interstitial free peptide are more relevant. For lower amounts the perfusion is more important. Therefore, the optimal amount depends on the perfusion, binding site density, serum volume and interstitial volume ratios and on unspecific kidney uptake. The same holds true for salivary glands besides the unspecific uptake.

In Table 4, for amounts of 32–512 nmol the ratio of the optimal to actual tumor BED, considering maximal tolerable absorbed or effective doses for kidneys and salivary glands and red marrow is presented. The potential improvement varied substantially (factor of 1.0–3.0) between patients and tumor lesions.

**Tumor perfusion sensitivity analysis.** For all patients, the assumption of tumor perfusion rate 0.01 ml·g\textsuperscript{-1}·min\textsuperscript{-1} was not supported by the data (Akaike weights < 1%). In 3 patients, perfusion rates for 0.1, 0.5 and 1 ml·g\textsuperscript{-1}·min\textsuperscript{-1} yielded acceptable results (Table 2, S3 File). For all patients, the average Akaike weights for the assumptions of 0.1, 0.5 and 1 were 19%, 33% and
47%, respectively. Using the weights, an average rate of 0.66 ml g\(^{-1}\) min\(^{-1}\) was calculated. This value is close to the value [27] that was taken from the literature (S1 File) for primary tumors. These assumptions led to the same time-integrated-activity-coefficient, i.e., when fitting lower fixed perfusion rates were compensated by higher binding site densities. Fig 4 shows for patient 2 how the chosen perfusion rate affects the predicted tumor BED for other amounts and activities. For amounts, as they were actually used, the tumor BED is less sensitive to the chosen perfusion rate than for smaller amounts. The differences of the predicted tumor BED for the optimal amount (for 32–512 nmol) and activity, considering kidney and salivary glands and red marrow as dose limiting, ranged from 0.6–20%.

**Discussion**

To investigate the effect of peptide and activity amount on the tumor-to-kidney and tumor-to-salivary glands BED ratio in \(^{177}\)Lu-labeled PSMA-targeted therapy, we applied a recently developed (and herein modified) modeling approach [11] that allows optimizing the PSMA ligand amount and activity taking into account maximum tolerable absorbed doses for the salivary glands and biologically effective doses for the kidneys and red marrow.

The PBPK model described the data well regarding visual inspection, coefficients of determination and variation and correlation of parameters. In general, the estimated parameters were in a physiologically reasonable range. The estimated ratio of PSMA expression of tumor-to-kidney or tumor-to-salivary gland is lower than reported in the literature [5, 43]. However, the mean value (~230,000 per cell) and the range (~12,000 to ~1.5\( \times\)10\(^6\) per cell) of estimated
PSMA expression rates of the investigated tumors compare favorably with in vitro experiments for various cell lines and different PSMA specific ligands [14–16] assuming $10^{12}$ cells/l tumor (Table 2). Therefore, the higher than expected estimated PSMA expression rates might also include/mimic unspecific binding, which was neglected (in the model) in the salivary glands and was assumed low in the kidneys [9]. The kidney pharmacokinetic model structure and parameters for unspecific uptake were adopted from [11] assuming similar effective blocking of unspecific uptake using amino acids. The importance of non-PSMA specific uptake in the kidneys and salivary glands has to be elucidated in further work.

The sensitivity analysis of the tumor perfusion rate showed that the choice of the fixed values, if preselected with the AICc, had no great effect on the tumor BED, if the optimal amount is large. However, the extrapolation to smaller amounts led to considerably different results (Fig 4). In the light of the attempt of some working groups to use PET for pre-therapeutic dosimetry, extrapolation from measurements using small amounts of peptide to therapy with substantially higher amounts should be further investigated [44].

The performed simulations showed that for a fixed ratio of tumor-to-kidney blood flow rates (here ~ 1/5) the ratio of tumor-to-kidneys binding site density (here ~ 1.4–77) is the most important quantity that determines the location of the optimum (optimal amount) if the kidney is considered the limiting organ. In addition, the binding site density ratio is also the most important quantity that determines the maximal possible BED ratio. Unspecific kidney uptake (although assumed to be low) and the tumor-to-kidney ratio of interstitial and serum volume fractions become more relevant with larger administered amounts. The actual BED ratio is therefore

| Patient | Tumor lesion | Activity [GBq] | Amount [nmol] | D [Gy] | BED [Gy] | D [Gy] | BED [Gy] |
|---------|--------------|----------------|---------------|--------|----------|--------|----------|
| P1      | Injection    | 22.5           | 512           | 156    | 234      | 10     | 11       |
|         | Tumor        |                |               |        |          |        |          |
| P2      | Injection    | 13.9           | 64            | 46     | 52       | 20     | 24       |
|         | Tumor        |                |               |        |          |        |          |
| P3      | Injection    | 8.0            | 2             | 16     | 17       | 14     | 14       |
|         | Tumor        |                |               |        |          |        |          |
| P4      | Injection    | 7.9            | 64            | 24     | 26       | 8.9    | 9.7      |
|         | Tumor        |                |               |        |          |        |          |
| P5      | Injection    | 9.3            | 256           | 29     | 32       | 14     | 15       |
|         | Tumor        |                |               |        |          |        |          |
| Mean    | Activity     | 12.5           | 211           | 93     | 154      | 18     | 22       |
|         | Amount       | 5.8            | 183           | 118    | 258      | 12     | 17       |
| Median  | Activity     | 9.3            | 192           | 44     | 48       | 14     | 15       |
|         | Amount       | 7.9            | 12            | 14     | 14       | 8.9    | 9.7      |
| Max     | Activity     | 22.5           | 512           | 390    | 850      | 40     | 54       |

Abbreviations: D absorbed dose, BED biologically effective dose

$a$ 1.66 μg of the ligand corresponds to 1 nmol. For these calculations, radiochemical limitations are not considered.

$b$ Kidney BED of 10 Gy corresponds to a D of 7.9±0.2 Gy and salivary gland D of 7.5 Gy to a BED of 8.1±0.1 Gy.

$c$ The simulated absorbed dose is high due to high tumor binding site concentration (2412 ± 802 nmol/l) and large injected activity. Therefore, the BED calculated using the linear quadratic model becomes extremely large. The linear quadratic model is probably not applicable for such large doses.

doi:10.1371/journal.pone.0162303.t003

Table 3. Optimal amounts (for $2^{13}$ nmol), pertaining activities, absorbed doses and biologically effective doses (BED).
predominantly determined by the actual number of bound ligand per organ mass. However, high ligand density necessitates both, a high binding site density and high binding site occupancy, i.e. high degree of saturation. The kidney binding sites are saturated with considerably lower amounts compared to most tumors due to the high kidney perfusion (≈2.5 ml g\(^{-1}\) min\(^{-1}\)) and medium (mean 27 nmol L\(^{-1}\)) binding site density. Therefore, for increasing amounts, the fraction bound or internalized peptide of the total applied peptide amount (and therefore the fraction of activity, as labeled and unlabeled are assumed to behave equally) decreases stronger in the kidney than in the tumor. Thus, compared to the kidney, the time-integrated activity coefficient of the tumor declines slower or even stays constant with increasing amounts depending on tumor perfusion and binding site density [9]. Higher amounts of activity are allowed for lower time-integrated activity coefficients in the kidney. This leads to an improved BED ratio for higher administered peptide amounts. For the investigated patients, the perfusion rates and binding site densities of the salivary glands and the tumor were more similar than for the kidneys and tumor. Therefore, the tumor-to-salivary glands BED ratio for was more similar for all amounts than for the kidney-to-tumor BED ratio.

In general, the simulations showed that the higher the ratio of tumor-to-kidney binding site density, the larger the effect of the amount of peptide on the BED ratio. In many cases, amounts, which are normally used for PET imaging (≈ 2−2\(^{3}\) nmol), led to considerably different tumor-to-kidney ratios than amounts used for therapy (≈ 2\(^{6}\)−2\(^{8}\) nmol) (Fig 3). However, for the investigated patients the therapeutic window was not specifically narrow and the actually injected amount close to the optimum (Table 4). Therefore, the potential improvement

![Blood flow sensitivity analysis](https://doi.org/10.1371/journal.pone.0162303.g004)

**Fig 4. Blood flow sensitivity analysis.** In panel A and B, the tumor BED for activity and peptide amount combinations (2−2\(^{13}\) nmol and red marrow BED < 0.25 Gy\(_{10}\)) that lead to a kidney BED of 10 Gy\(_{1.5}\) (A) or salivary gland BED of 7.5 Gy (B) is shown for different assumptions for the perfusion rate. The estimated parameters of patient 2 (bone tumor 1, lymph node tumor 2) were used. The results of all patients can be found in S3 File.

doi:10.1371/journal.pone.0162303.g004
(actual versus optimal) was small (factor 1–1.2) in 4 out of 5 patients. However, for lesions with high binding site density (e.g. 2412 ± 802 nmol/l in patient 1) larger amounts and activities would have been beneficial according to the presented simulations (tumor BED shows a 3 fold increase). The sensitivity analysis for the tumor perfusion rate also showed that larger amounts and activities are an option to increase the ratio for less well perfused tumors with average binding site densities. More data are required to identify whether a standard amount is sufficient for most patients or whether an individualization of the optimal amount is necessary. In both cases, however, the pertaining activity has to be determined depending on the number of intended cycles and the limit to the kidney and salivary glands.

Although we believe, due to the given physiological model structure and a priori knowledge, the estimated parameter values and simulations are a good approximation of the real physiological processes, pharmacokinetic data derived from 3D imaging techniques are required to further validate the method and to improve the prediction accuracy. For example, a more accurate determination of organ and tumor perfusion necessitates early 3D measurements. For the release rates, 2D measurements might be sufficient.

Even in case of perfect biokinetic data (no error, infinite number of measurements) and a perfect model (extrapolation from fitted curves to simulated TIACs correct), there are potential sources for errors. Inaccurate estimation of tumor and organ volume might lead to an error in the determined absorbed dose. The radiobiological parameters or the structure of BED model itself might not apply for high doses (Table 3, patient 1). In addition, it is not entirely clear which tolerable doses can be applied for this specific application. The absorbed dose instead of the BED for salivary glands was used as to our knowledge no general used BED tolerable dose is available for molecular radiotherapy. Using constrains for kidney (BED of 10 Gy) and for salivary glands (absorbed dose of 7.5 Gy), the salivary gland was the dose limiting organ in all patients for amounts of 32–512 nmol.

For the presented data, if higher tolerable absorbed doses to the salivary glands are assumed, optimizing the amount and activity becomes more important. The influence of a different number of cycles or different maximal tolerable doses on the tumor-to-kidney or salivary gland ratio and on the optimal amount is object to further investigations.

### Table 4. Ratio of BED for actually and optimal amounts (for 32–512 nmol) and activity.

| Patient | Tumor | Activity [GBq] | Amount [nmol] | Activity [GBq] | Amount [nmol] | \(D_{Tu_{optimal}}/D_{Tu_{actual}}\) [unity] | \(BED_{Tu_{optimal}}/BED_{Tu_{actual}}\) [unity] |
|---------|-------|--------------|--------------|--------------|--------------|---------------------------------|---------------------------------|
| P1      | 1     | 6.0          | 148          | 16.5         | 512          | 1.3                             | 1.4                             |
|         | 2     |              |              | 16.5         | 512          | 2.2                             | 3.0                             |
| P2      | 1     | 5.4          | 98           | 4.7          | 32           | 1.2                             | 1.2                             |
|         | 2     |              |              | 4.7          | 32           | 1.2                             | 1.2                             |
| P3      | 1     | 5.4          | 89           | 4.3          | 512          | 1.2                             | 1.2                             |
|         | 2     |              |              | 4.3          | 512          | 1.0                             | 1.0                             |
| P4      | 1     | 5.4          | 74           | 5.6          | 32           | 1.1                             | 1.1                             |
|         | 2     |              |              | 5.6          | 32           | 1.1                             | 1.1                             |
| P5      | 1     | 5.6          | 302          | 2.5          | 32           | 1.0                             | 1.0                             |
|         | 2     |              |              | 8.2          | 512          | 1.0                             | 1.0                             |

Abbreviations: D absorbed dose, BED biologically effective dose

*Considering kidney BED ≤ 10 Gy, salivary glands AD ≤ 7.5 Gy and RM BED < 0.25 Gy. Amounts of peptide are limited to 32–512 nmol*

doi:10.1371/journal.pone.0162303.t004
Conclusions

Based on PBPK model simulations, the effect of the peptide amount on the tumor-to-kidney BED ratio and the tumor-to-salivary glands BED ratio predominantly depends on the binding site density ratio and the ratio of perfusions (blood flow per mass). With increasing amounts of peptide, the influence of the perfusion decreases and the serum volume and interstitial volume ratios become more important. For the kidneys also the unspecific kidney uptake is increasingly important for larger amounts. For therapy, the currently given amounts of approximately 100–300 nmol yield favorable BED ratios for many lesions. However, there is potential in individually optimizing the amount of peptide and pertaining activity for tumors with high PSMA binding site densities relative to kidney and salivary glands. In addition, the BED of less well perfused tumors (<0.1 ml·g⁻¹·min⁻¹) with average binding site densities could be increased by using larger amounts and pertaining activities. The validation of the presented model and method is ongoing.

Supporting Information

S1 File. Equations, parameters and compartments. All differential equations and the compartmental model structure with the pertaining parameters and parameter values as well as the equations describing BED calculations.
(DOC)

S2 File. Fitting results and simulations. Estimated parameters, fitted curves as well as the pertaining BED simulations for all patients.
(PPTX)

S3 File. Tumor perfusion analysis. BED simulations for all patients with varying blood flows to the tumor.
(PPTX)

Acknowledgments

The authors gratefully acknowledge grants by the Deutsche Forschungsgemeinschaft (German Research Foundation, DFG KL 2742/2-1, BE 4393/1-1 and GL 236/11-1).

Author Contributions

Conceived and designed the experiments: PK GG AB RB.
Performed the experiments: PK CS HK MS AS.
Analyzed the data: PK CS.
Wrote the paper: PK CS RB AB GG.

References

1. Pilestroff, Luster M, Jilg CA, Olbert PJ, Ohlmann CH, Lassmann M, et al. Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks. Eur J Nucl Med Mol Imaging. 2015; 42(13):1971–5. doi: 10.1007/s00259-015-3186-3 PMID: 26373947.
2. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. Lutetium-177 PSMA Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016.
3. Baum R, Kulkarni H, Volkmer B, Bohuslavizki K, Schuchardt C, Klette I, et al. Theranostik des metastasierten Prostatakarzinoms mittels Lu-177 PSMA-Liganden in Kombination mit Ga-68 PSMA PET/CT. Der Nuklearmediziner. 2015; 38(02):145–52. doi: 10.1055/s-0035-1549991

4. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995; 62(5):552–8. PMID: 7665226.

5. O’Keefe DS, Bacich DJ, Heston WD. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate. 2004; 58(2):200–10. doi: 10.1002/pro.10319 PMID: 14716746.

6. Kabasakal L, AbuQbeita M, Aygun A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42(13):1976–83. doi: 10.1007/s00259-015-3125-3 PMID: 26227531.

7. Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016; 43(1):42–51. doi: 10.1007/s00259-015-3174-7 PMID: 26318602.

8. Kratochwil C, Giesel FL, Eder M, Hoppe-Tich T, Youssoufian H, et al. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med. 2015; 56(2):293–8. doi: 10.2967/jnumed.114.147181 PMID: 25613537.

9. Kletting P, Muller B, Erentok B, Schmaljohann J, Behrendt FF, Reske SN, et al. Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Med Phys. 2012; 39(9):5708–17. doi: 10.1118/1.4747266 PMID: 22957636.

10. Kletting P, Maass C, Reske S, Beer AJ, Glattung G. Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy. PLoS One. 2015; 10(5):e0127934. doi: 10.1371/journal.pone.0127934 PMID: 26010360; PubMed Central PMCID: PMC4444288.

11. Kletting P, Kull T, Maass C, Malik N, Luster M, Beer AJ, et al. Optimized Peptide Amount and Activity for 90Y-Labeled DOTATATE Therapy. J Nucl Med. 2016; 57(4):503–8. doi: 10.2967/jnumed.115.164999 PMID: 26678617.

12. Sabet A, Nagarajah J, Dogan AS, Biersack HJ, Sabet A, Guhlke S, et al. Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors. EJNMMI research. 2013; 3(1):82. doi: 10.1186/2191-219X-3-82 PMID: 24369055; PubMed Central PMCID: PMC3877953.

13. Schuler E, Osterlund A, Forsell-Aronsson E. The amount of injected 177Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice. Acta Oncol. 2016; 55(1):68–76. doi: 10.3109/02841869.2015.1027001 PMID: 25813472.

14. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000; 60(18):5237–43. PMID: 11016653.

15. Holland JP, Divivel V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunopET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010; 51(8):1293–300. doi: 10.2967/jnumed.110.076714 PMID: 20660376; PubMed Central PMCID: PMC2996794.

16. Wang X, Ma D, Olson WC, Heston WD. In vitro and in vivo responses of advanced prostate tumors to 90Y-labeled DOTATATE Therapy. J Nucl Med. 2015; 57(1):80–8. doi: 10.2967/jnumed.114.147181 PMID: 26116124.

17. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirz M, Wiessalla S, et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016. doi: 10.2967/jnumed.115.169443 PMID: 26795286.

18. Bubeck B. Renal clearance determination with one blood sample: improved accuracy and universal applicability by a new calculation principle. Semin Nucl Med. 1993; 23(1):73–86. PMID: 8469997.

19. Weinseisen M, Simecek J, Schottelius M, Schweiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI research. 2014; 4(1):63. doi: 10.1186/s13550-014-0063-1 PMID: 26161124; PubMed Central PMCID: PMC4452638.

20. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KA, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1989; 40(2):375–61S. PMID: 20392948.

21. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature. J Nucl Med. 2009; 50(3):477–84. doi: 10.2967/jnumed.108.096036 PMID: 19298298.
22. Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Muller D, Baum RP. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using $^{177}$Lu-DOTATATE, $^{177}$Lu-DOTANOC, and $^{177}$Lu-DOTATOC. Recent Results Cancer Res. 2013; 194:519–36. doi: 10.1007/978-3-642-27994-2_30 PMID: 22918780.

23. Breau RH, Clark E, Bruner B, Cervini P, Atwell T, Knoll G, et al. A simple method to estimate renal volume from computed tomography. Canadian Urological Association Journal = Journal de l’Association des urologues du Canada. 2013; 7(5–6):189–92. PubMed Central PMCID: PMC3699080.

24. Ben Jemaa A, Bouraoui Y, Sallami S, Banasr A, Ben Rais N, Ouertani L, et al. Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostate pathologies. J Exp Clin Cancer Res. 2010; 29:171. doi: 10.1186/1756-9966-29-171 PMID: 21189143; PubMed Central PMCID: PMC3032682.

25. Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism. 1998; 47(4):484–92. PMID: 9550550.

26. Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. $^{68}$Ga- and $^{177}$Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med. 2015; 56(8):1169–76. doi: 10.2967/jnumed.115.158550 PMID: 26089548.

27. Luczyńska E, Heinze-Paluchowska S, Blecharz P, Jereczek-Fossa B, Petralia G, Bellomi M, et al. Correlation between CT perfusion and clinicopathological features in prostate cancer: a prospective study. Med Sci Monit. 2015; 21:153–62. doi: 10.12659/MSM.891401 PMID: 25582437; PubMed Central PMCID: PMC4501466.

28. Winter G, Drescher A, Baur B, Solbach C, Reske SN, Beer AJ. Comparative analysis of chelator-modified peptides for imaging of prostate carcinoma. Annual Congress EANM. 2014; (P200).

29. Giatting G, Kletting P, Reske SN, Hohl K, Ring C. Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys. 2007; 34(11):4285–92. doi: 10.1118/1.2794176 PMID: 18072493.

30. Kletting P, Giatting G. Model selection and inference in pharmacokinetics: The corrected Akaike information criterion and the F-test. Z Med Phys. 2009; 19(3):200–6. PMID: 19761098.

31. Kletting P, Schimmel S, Kestler HA, Hanscheid H, Luster M, Fernandez M, et al. Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys. 2013; 40(10):102504. doi: 10.1118/1.4820367 PMID: 24089925.

32. Koenigsmann M. From imaging to dosimetry and biological effects. Q J Nucl Med Mol Imaging. 2011; 55(1):44–56. PMID: 21398784.

33. Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010; 37(6):1238–50. doi: 10.1007/s00259-010-1422-4 PMID: 20411259.

34. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with $^{90}$Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005; 46(Suppl 1):99S–106S. PMID: 15653658.

35. Strigari L, Koenigsmann M, Chiesa C, Bardies M, Du Y, Gleisner KS, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014; 41(10):1280–92. doi: 10.1007/s00259-014-2824-5 PMID: 24915892.

36. Cremonesi M, Bottia F, Di Dio A, Ferrari M, Bodei L, De Cicco C, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging. 2010; 54(1):37–51. PMID: 20168285.

37. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The Second-Generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine. J Nucl Med. 2005; 46(6):1023–7. PMID: 15937151.

38. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a $^{124}$I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014; 41(7):1280–92. doi: 10.1007/s00259-014-2713-y PMID: 24577951; PubMed Central PMCID: PMC4052014.

39. Hobbs RF, Jentzen W, Bockisch A, Sgourou G. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radiiodine treatment of differentiated thyroid cancer estimated using $^{124}$I PET. Q J Nucl Med Mol Imaging. 2013; 57(1):79–91. PMID: 23474639; PubMed Central PMCID: PMC4037814.

40. Kal HB, Van Gellekom MP. How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys. 2003; 57(4):1116–21. PMID: 14575844.

41. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985; 58(690):515–28. PMID: 2063711.
42. Schwenzer NF, Schraml C, Martirosian P, Boss A, Claussen CD, Schick F. MR measurement of blood flow in the parotid gland without contrast medium: a functional study before and after gustatory stimulation. NMR in biomedicine. 2008; 21(6):598–605. doi: 10.1002/nbm.1231 PMID: 18072228.

43. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett. 2006; 236(2):229–38. PMID: 16046056

44. Hardiansyah D, Maass C, Attarwala AA, Muller B, Kletting P, Mottaghy FM, et al. The role of patient-based treatment planning in peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2016; 43(5):871–80. doi: 10.1007/s00259-015-3248-6 PMID: 26577941.